This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Care Stocks to Watch in 2010

Is the Merck scenario any healthier?

Many health care experts argue that if an investor wants to get healthy gains with big pharma in 2010, Merck (MRK ) is the more potent story.

Merck is also in the middle of merger integration, with Schering-Plough. The deal has received much more praise from the market than the Pfizer-Wyeth marriage. Still, how much better is Merck's positioning that Pfizer?

When it comes down to the all-important future pipeline question, Merck's research and development is considered meaningfully greater than the pipeline at Pfizer. "You expect 90% of R&D efforts to fail, not 100%," said Les Funtleyder, an analyst with Miller Tabak, when comparing Merck to Pfizer.

Merck and Schering also have a far better history than Pfizer of developing new compounds. And Funtleyder noted that patent-expiring Lipitor papered over a lot of R&D failures for Pfizer. Merck bought time to develop its pipeline with the deal, and in the most bullish scenario for its drug pipeline, Merck will be the big pharma stock that could switch from a defensive play to a growth company.

If you're still a bear on economic recovery, healthcare stocks like the big pharmaceuticals often make good defensive bets. Still, analysts caution investors who are looking for big growth stories from pharmaceuticals in 2010 to steer clear of the Superbowl-advertising drug stocks, and look to the biotechnology sector.
2 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
CERN $60.93 -1.10%
BSX $16.68 1.90%
CI $136.24 -0.95%
MRK $54.01 -0.75%
PFE $32.88 1.40%

Markets

Chart of I:DJI
DOW 16,394.44 +108.93 0.67%
S&P 500 1,958.73 +18.22 0.94%
NASDAQ 4,746.6860 +49.15 1.05%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs